Drug,Chemical Structure,Adverse Effect / Toxicity,Species,Dose,Dose Type,Route,Source,Source Link,Year,no_stereoisomer
Abemaciclib,CCN1CCN(CC1)CC1=CC=C(NC2=NC=C(F)C(=N2)C2=CC3=C(N=C(C)N3C(C)C)C(F)=C2)N=C1,Hepatic function abnormal,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 208716/S-000 Part 09, page:37 PDF 678k",https://www.pharmapendium.com/browse/fda/Abemaciclib/a50315d3a726a8049e1d15f32cd253cf?reference=37,2017.0,CCN1CCN(CC1)CC1=CC=C(NC2=NC=C(F)C(=N2)C2=CC3=C(N=C(C)N3C(C)C)C(F)=C2)N=C1
Acebutolol Hydrochloride,CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(=C1)C(C)=O,Hepatic function abnormal,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Approval Package 018917/S-001 Part 10, page:14 PDF 1636k",https://www.pharmapendium.com/browse/fda/Acebutolol Hydrochloride/ff5c94ac791b1b59972237e93367ae39?reference=14,1984.0,CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(=C1)C(C)=O
Acetazolamide Sodium,C\C([O-])=N\C1=NN=C(S1)S(N)(=O)=O,Hepatic function abnormal,Human,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 012945/S-037, S-038 Part 02, page:8 PDF 504k",https://www.pharmapendium.com/browse/fda/Acetazolamide Sodium/e5d463a87cd4eaec3059a7a016e6cf9b?reference=8,2005.0,C\C([O-])=N\C1=NN=C(S1)S(N)(=O)=O
Adefovir Dipivoxil,CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCOC(=O)C(C)(C)C,Hepatic function abnormal,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021449/S-000 Part 01, page:11 PDF 1194k",https://www.pharmapendium.com/browse/fda/Adefovir Dipivoxil/bc3aff4607718a9708d49744dbed7ebc?reference=11,2002.0,CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCOC(=O)C(C)(C)C
Agomelatine,COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1,Hepatic function abnormal,Human,-1.6989700043360187,Repeated,Oral,"EMA approval document: Assessment Report EMA/702809/2013; EMEA/H/C/000915/PSUV/0017; EMEA/H/C/000916/PSUV/0019, page:43 PDF 3542k",https://www.pharmapendium.com/browse/ema/Agomelatine/89a6f9f624ebb2e3477a0213e0e6a953?reference=43,2013.0,COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1
Amiloride Hydrochloride,NC(=N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1,Hepatic function abnormal,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 018200 Part 09, page:7 PDF 2048k",https://www.pharmapendium.com/browse/fda/Amiloride Hydrochloride/f8fe084be70936382c723096a4a446f6?reference=7,1981.0,NC(=N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1
Aminosalicylic Acid,NC1=CC=C(C(O)=O)C(O)=C1,Hepatic function abnormal,Human,-4.301029995663981,Repeated,Oral,"EMA approval document: Assessment Report EMA/18511/2014; EMEA/H/C/002709, page:45 PDF 599k",https://www.pharmapendium.com/browse/ema/Aminosalicylic Acid/5dc1c7670344f7aeae3c895ff5c6d510?reference=45,2013.0,NC1=CC=C(C(O)=O)C(O)=C1
Amiodarone Hydrochloride,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,Hepatic function abnormal,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Approval Package 018972/S-014 Part 13, page:22 PDF 4900k",https://www.pharmapendium.com/browse/fda/Amiodarone Hydrochloride/f4944cf744f11785c20123f7038cc342?reference=22,1983.0,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1
Amphotericin B Liposome,C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@H]([C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@H](C)[C@@H](O)[C@H]1C)O2)C(O)=O,Hepatic function abnormal,Human,-0.47712125471966244,Repeated,Intravenous,"FDA approval package document: Medical Officer Review 050740/S-000 Part 01, page:30 PDF 1551k",https://www.pharmapendium.com/browse/fda/Amphotericin B Liposome/19d5d0daddbe2dbdf5768428b0cd5659?reference=30,1997.0,C[CH]1OC(=O)C[CH](O)C[CH](O)CC[CH](O)[CH](O)C[CH](O)C[C]2(O)C[CH](O)[CH]([CH](C[CH](O[CH]3O[CH](C)[CH](O)[CH](N)[CH]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[CH](C)[CH](O)[CH]1C)O2)C(O)=O
Anagrelide Hydrochloride,ClC1=C(Cl)C2=C(C=C1)N=C1NC(=O)CN1C2,Hepatic function abnormal,Human,-0.6989700043360189,Repeated,Oral,"EMA approval document: ANNEX I, page:4 PDF 301k",https://www.pharmapendium.com/browse/ema/Anagrelide Hydrochloride/c38efdb6ee6f0cf78e1ce7d0dd880ad3?reference=4,2020.0,ClC1=C(Cl)C2=C(C=C1)N=C1NC(=O)CN1C2
Anidulafungin,CCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@@H](C)O,Hepatic function abnormal,Human,-0.6989700043360189,Repeated,Intravenous,"EMA approval document: ANNEX I, page:4 PDF 246k",https://www.pharmapendium.com/browse/ema/Anidulafungin/b0126dc536ecaaa2fca7659f1a5064c5?reference=4,2020.0,CCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[CH]1C[CH](O)[CH](O)NC(=O)[CH]2[CH](O)[CH](C)CN2C(=O)[CH](NC(=O)[CH](NC(=O)[CH]2C[CH](O)CN2C(=O)[CH](NC1=O)[CH](C)O)[CH](O)[CH](O)C1=CC=C(O)C=C1)[CH](C)O
Apixaban,COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O,Hepatic function abnormal,Human,-1.3010299956639813,Repeated,Oral,"EMA approval document: Assessment Report EMA/478338/2014; EMEA/H/C/002148/II/0014/G, page:82 PDF 2588k",https://www.pharmapendium.com/browse/ema/Apixaban/63204c7b176325279d63eef03f2d71ff?reference=82,2014.0,COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O
Argatroban,C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C1=C2NCC(C)CC2=CC=C1,Hepatic function abnormal,Human,-2.6989700043360187,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 020883/S-000 Part 02, page:16 PDF 1482k",https://www.pharmapendium.com/browse/fda/Argatroban/b122a5989d050ed712a3caf647e9286a?reference=16,2000.0,C[CH]1CCN([CH](C1)C(O)=O)C(=O)[CH](CCCNC(N)=N)NS(=O)(=O)C1=C2NCC(C)CC2=CC=C1
Aripiprazole,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl,Hepatic function abnormal,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Approval Package 021436/S-019, S-020, S-022; 021713/S-014 Part 10, page:16 PDF 3580k",https://www.pharmapendium.com/browse/fda/Aripiprazole/de18cdf02f2dcd6fecbf15cd801fba12?reference=16,2008.0,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
Atorvastatin Calcium,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(N1CC[C@@H](O)C[C@@H](O)CC([O-])=O)C1=CC=C(F)C=C1,Hepatic function abnormal,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 090548/S-000 Part 02, page:108 PDF 17624k",https://www.pharmapendium.com/browse/fda/Atorvastatin Calcium/991c36797f7df2a7d600ecd1ff35fccb?reference=108,2011.0,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(N1CC[CH](O)C[CH](O)CC([O-])=O)C1=CC=C(F)C=C1
Atovaquone,OC1=C([C@H]2CC[C@@H](CC2)C2=CC=C(Cl)C=C2)C(=O)C2=C(C=CC=C2)C1=O,Hepatic function abnormal,Human,-3.1760912590556813,Repeated,Oral,"FDA approval package document: Approval Package 020500 Part 01, page:23 PDF 5690k",https://www.pharmapendium.com/browse/fda/Atovaquone/6408b8416662f3a0f75960d17cfa8032?reference=23,1995.0,OC1=C([CH]2CC[CH](CC2)C2=CC=C(Cl)C=C2)C(=O)C2=C(C=CC=C2)C1=O
Axitinib,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=NC=CC=C3)=C2)C=CC=C1,Hepatic function abnormal,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202324/S-000 Part 05, page:22 PDF 323k",https://www.pharmapendium.com/browse/fda/Axitinib/4732e3524b795cb6ae3100690e755c8b?reference=22,2011.0,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=NC=CC=C3)=C2)C=CC=C1
Azithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,Hepatic function abnormal,Human,-2.6989700043360187,Repeated,Oral/intravenous,"FDA approval package document: Label 050809/S-000, page:15 PDF 1584k",https://www.pharmapendium.com/browse/fda/Azithromycin/0c2ef5a844f20b7e1b10400ba21520ef?reference=15,2006.0,CC[CH]1OC(=O)[CH](C)[CH](O[CH]2C[C](C)(OC)[CH](O)[CH](C)O2)[CH](C)[CH](O[CH]2O[CH](C)C[CH]([CH]2O)N(C)C)[C](C)(O)C[CH](C)CN(C)[CH](C)[CH](O)[C]1(C)O
Aztreonam,C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O,Hepatic function abnormal,Human,-3.4771212547196626,Repeated,Parenteral,"FDA approval package document: Approval Package 050580 Part 01, page:8 PDF 8962k",https://www.pharmapendium.com/browse/fda/Aztreonam/6c273762992adaf8c1f986d26d8f0572?reference=8,1986.0,C[CH]1[CH](NC(=O)C(=N/OC(C)(C)C(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O
Balsalazide Disodium,OC1=CC=C(C=C1C([O-])=O)\N=N\C1=CC=C(C=C1)C(=O)NCCC([O-])=O,Hepatic function abnormal,Human,-0.3010299956639812,Repeated,Oral,"FDA approval package document: Label 022205/S-000, page:5 PDF 1039k",https://www.pharmapendium.com/browse/fda/Balsalazide Disodium/39f42c3ed4963ef1763049c817e6579c?reference=5,2012.0,OC1=CC=C(C=C1C([O-])=O)\N=N\C1=CC=C(C=C1)C(=O)NCCC([O-])=O
Bempedoic Acid,CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O,Hepatic function abnormal,Human,-2.255272505103306,Repeated,Oral,"FDA approval package document: Approval Package 211616/S-000 Part 11, page:40 PDF 1857k",https://www.pharmapendium.com/browse/fda/Bempedoic Acid/2208c196ea39d0c896405f6c8e825e31?reference=40,2019.0,CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O
Benazepril Hydrochloride,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCC2=CC=CC=C2N(CC(O)=O)C1=O,Hepatic function abnormal,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 019851/S-028 Part 01, page:6 PDF 896k",https://www.pharmapendium.com/browse/fda/Benazepril Hydrochloride/4f8ff320f464e197b44807e1d29ca46d?reference=6,2003.0,CCOC(=O)[CH](CCC1=CC=CC=C1)N[CH]1CCC2=CC=CC=C2N(CC(O)=O)C1=O
Bicalutamide,CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC=C(C#N)C(=C1)C(F)(F)F,Hepatic function abnormal,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 020498/S-004 Part 01, page:13 PDF 2075k",https://www.pharmapendium.com/browse/fda/Bicalutamide/63bfb67c59a0bdab331711fa55faff9d?reference=13,1995.0,CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC=C(C#N)C(=C1)C(F)(F)F
Binimetinib,CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C=C12)C(=O)NOCCO,Hepatic function abnormal,Human,-1.6532125137753437,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/CHMP/554701/2018; EMEA/H/C/004579/0000, page:177 PDF 7846k",https://www.pharmapendium.com/browse/ema/Binimetinib/7ff4ee13f77542f6f02b01b8fe161ec1?reference=177,2018.0,CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C=C12)C(=O)NOCCO
Bosentan,COC1=CC=CC=C1OC1=C(OCCO)N=C(N=C1NS(=O)(=O)C1=CC=C(C=C1)C(C)(C)C)C1=NC=CC=N1,Hepatic function abnormal,Human,-2.0969100130080562,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021290/S-001, page:25 PDF 891k",https://www.pharmapendium.com/browse/fda/Bosentan/018ecab3c97955ac0145961b8921fe86?reference=25,2003.0,COC1=CC=CC=C1OC1=C(OCCO)N=C(N=C1NS(=O)(=O)C1=CC=C(C=C1)C(C)(C)C)C1=NC=CC=N1
Bosutinib Monohydrate,COC1=C(Cl)C=C(Cl)C(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C1,Hepatic function abnormal,Human,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Label 203341/S-000 Part 01, page:8 PDF 255k",https://www.pharmapendium.com/browse/fda/Bosutinib Monohydrate/7cc0c4a61ee492874395acfd95f0c9f8?reference=8,2012.0,COC1=C(Cl)C=C(Cl)C(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C1
Bupropion Hydrochloride,CC(NC(C)(C)C)C(=O)C1=CC=CC(Cl)=C1,Hepatic function abnormal,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Review 077285/S-000, page:8 PDF 2859k",https://www.pharmapendium.com/browse/fda/Bupropion Hydrochloride/4670270ed4f0750f946dd93e73bbac0a?reference=8,2008.0,CC(NC(C)(C)C)C(=O)C1=CC=CC(Cl)=C1
Busulfan,CS(=O)(=O)OCCCCOS(C)(=O)=O,Hepatic function abnormal,Human,-0.3010299956639812,Repeated,Intravenous,"EMA approval document: Assessment Report EMA/550530/2014; EMEA/H/C/000472/II/0019, page:62 PDF 3214k",https://www.pharmapendium.com/browse/ema/Busulfan/460abbd9922582c61fed776c0dce34a2?reference=62,2014.0,CS(=O)(=O)OCCCCOS(C)(=O)=O
Capmatinib Hydrochloride,CNC(=O)C1=CC=C(C=C1F)C1=NN2C(CC3=CC=C4N=CC=CC4=C3)=CN=C2N=C1,Hepatic function abnormal,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 213591/S-000 Part 09, page:22 PDF 1046k",https://www.pharmapendium.com/browse/fda/Capmatinib Hydrochloride/eab6c5d203e9be4cefc241fe3fad3c0a?reference=22,2020.0,CNC(=O)C1=CC=C(C=C1F)C1=NN2C(CC3=CC=C4N=CC=CC4=C3)=CN=C2N=C1
Captopril,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O,Hepatic function abnormal,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Approval Package 018343/S-013, S-005, S-018 Part 11, page:44 PDF 2555k",https://www.pharmapendium.com/browse/fda/Captopril/a6dafa132eee9d55eb002caded1eba78?reference=44,1980.0,C[CH](CS)C(=O)N1CCC[CH]1C(O)=O
Carbamazepine,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,Hepatic function abnormal,Human,-3.0791812460476247,Repeated,Oral,"FDA approval package document: Approval Package 018281/S-003, S-001, S-004, S-005, S-022, S-015, S-006, S-008, S-009; 016608/S-053, S-055, S-056, S-048, S-058, S-059 Part 08, page:42 PDF 7022k",https://www.pharmapendium.com/browse/fda/Carbamazepine/dc5bcb1104d64bfe3f923577b248f246?reference=42,1981.0,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
Cariprazine Hydrochloride,CN(C)C(=O)N[C@H]1CC[C@@H](CC1)CCN1CCN(CC1)C1=CC=CC(Cl)=C1Cl,Hepatic function abnormal,Human,-1.0791812460476249,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 204370/S-000 Part 13, page:10 PDF 20439k",https://www.pharmapendium.com/browse/fda/Cariprazine Hydrochloride/de5cf9e7986f6516f669c2c34fd176f7?reference=10,2013.0,CN(C)C(=O)N[CH]1CC[CH](CC1)CCN1CCN(CC1)C1=CC=CC(Cl)=C1Cl
Cefadroxil,[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O,Hepatic function abnormal,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Approval Package 050527/S-009, page:29 PDF 2946k",https://www.pharmapendium.com/browse/fda/Cefadroxil/8f1f4d9eb86135ccadf08e3cb7095dbf?reference=29,1991.0,[H][C]12SCC(C)=C(N1C(=O)[CH]2NC(=O)[CH](N)C1=CC=C(O)C=C1)C(O)=O
Cefdinir,[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O,Hepatic function abnormal,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 050749/S-000 Part 04, page:62 PDF 2961k",https://www.pharmapendium.com/browse/fda/Cefdinir/d4125c172b18c868e68f4277dbb59547?reference=62,1996.0,[H][C]12SCC(C=C)=C(N1C(=O)[CH]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O
Cefepime Hydrochloride,CO\N=C(C(=O)N[C@H]1[C@H]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)\C1=CSC(N)=N1,Hepatic function abnormal,Human,-3.3010299956639813,Repeated,Parenteral,"FDA approval package document: Approval Package 050679 Part 06, page:94 PDF 6772k",https://www.pharmapendium.com/browse/fda/Cefepime Hydrochloride/fa0ab5e20b28f5ec593cdb93c27a8595?reference=94,1996.0,CO\N=C(C(=O)N[CH]1[CH]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)\C1=CSC(N)=N1
Cefmenoxime Hydrochloride,CO\N=C(C(=O)N[C@H]1[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O)\C1=CSC(N)=N1,Hepatic function abnormal,Human,-3.3010299956639813,Repeated,Parenteral,"FDA approval package document: Approval Package 050571 Part 01, page:10 PDF 5151k",https://www.pharmapendium.com/browse/fda/Cefmenoxime Hydrochloride/d2aca4fcb286f5a4bc51c0e42c7c6d63?reference=10,1987.0,CO\N=C(C(=O)N[CH]1[CH]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O)\C1=CSC(N)=N1
Cefmetazole Sodium,CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C([O-])=O,Hepatic function abnormal,Human,-3.6020599913279625,Repeated,Parenteral,"FDA approval package document: Approval Package 050637 Part 04, page:52 PDF 6408k",https://www.pharmapendium.com/browse/fda/Cefmetazole Sodium/61867a5e5606504d9f1213d3ad346a7d?reference=52,1989.0,CO[C]1(NC(=O)CSCC#N)[CH]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C([O-])=O
Cefpodoxime Proxetil,COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N\OC)\C1=CSC(N)=N1)C2=O)C(=O)OC(C)OC(=O)OC(C)C,Hepatic function abnormal,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Approval Package 050687 Part 01, page:23 PDF 4381k",https://www.pharmapendium.com/browse/fda/Cefpodoxime Proxetil/5ffa088364de86a8a3c0e1d525cdef88?reference=23,1992.0,COCC1=C(N2[CH](SC1)[CH](NC(=O)C(=N\OC)\C1=CSC(N)=N1)C2=O)C(=O)OC(C)OC(=O)OC(C)C
Ceftazidime,[H][C@]12SCC(C[N+]3=CC=CC=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC(N)=N1)C([O-])=O,Hepatic function abnormal,Human,-3.4771212547196626,Repeated,Parenteral,"FDA approval package document: Approval Package 050646 Part 01, page:28 PDF 5617k",https://www.pharmapendium.com/browse/fda/Ceftazidime/04d84e2f3ec0d275868d36da01f7904e?reference=28,1991.0,[H][C]12SCC(C[N+]3=CC=CC=C3)=C(N1C(=O)[CH]2NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC(N)=N1)C([O-])=O
Ceftazidime Sodium,[H][C@@]12SCC(C[N+]3=CC=CC=C3)=C(N1C(=O)[C@@H]2NC(=O)C(=N/OC(C)(C)C([O-])=O)\C1=CSC(N)=N1)C([O-])=O,Hepatic function abnormal,Human,-3.4771212547196626,Repeated,Parenteral,"FDA approval package document: Approval Package 050634 Part 01, page:9 PDF 6887k",https://www.pharmapendium.com/browse/fda/Ceftazidime Sodium/afaee6f95b5d88b21381d60115d3b531?reference=9,1969.0,[H][C]12SCC(C[N+]3=CC=CC=C3)=C(N1C(=O)[CH]2NC(=O)C(=N/OC(C)(C)C([O-])=O)\C1=CSC(N)=N1)C([O-])=O
Cefuroxime Axetil,CO\N=C(C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OC(C)OC(C)=O)\C1=CC=CO1,Hepatic function abnormal,Human,-3.0,Repeated,Oral,"FDA approval package document: Approval Package 050605 Part 08, page:1 PDF 1614k",https://www.pharmapendium.com/browse/fda/Cefuroxime Axetil/848e4186552e2f9a509fbb09911f3d88?reference=1,1985.0,CO\N=C(C(=O)N[CH]1[CH]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OC(C)OC(C)=O)\C1=CC=CO1
Cefuroxime Sodium,[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CC=CO1)C([O-])=O,Hepatic function abnormal,Human,-3.3521825181113627,Repeated,Parenteral,"FDA approval package document: Approval Package 050558 Part 02, page:17 PDF 6803k",https://www.pharmapendium.com/browse/fda/Cefuroxime Sodium/fc90108222828c291df893f3cd2a639c?reference=17,1983.0,[H][C]12SCC(COC(N)=O)=C(N1C(=O)[CH]2NC(=O)C(=N/OC)\C1=CC=CO1)C([O-])=O
Celecoxib,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F,Hepatic function abnormal,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Printed Labeling 020998/S-016, page:17 PDF 1618k",https://www.pharmapendium.com/browse/fda/Celecoxib/3576faf2cb1fb8e3a2f1aee0f7003ad9?reference=17,2003.0,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
Cenobamate,NC(=O)O[C@@H](CN1N=CN=N1)C1=CC=CC=C1Cl,Hepatic function abnormal,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 212839/S-000 Part 09, page:22 PDF 1279k",https://www.pharmapendium.com/browse/fda/Cenobamate/f9f6b5a7bbf7d9f56a6d509dfbe6d18b?reference=22,2019.0,NC(=O)O[CH](CN1N=CN=N1)C1=CC=CC=C1Cl
Ceritinib,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1,Hepatic function abnormal,Human,-2.8750612633917,Repeated,Oral,"EMA approval document: Assessment Report EMA/386332/2017; EMEA/H/C/003819/II/0012, page:93 PDF 6439k",https://www.pharmapendium.com/browse/ema/Ceritinib/0ce99201261a9d8e84a0cbcfc52ed714?reference=93,2017.0,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
Cetirizine Hydrochloride,OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,Hepatic function abnormal,Human,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 019835/S-015; 020346/S-008, page:17 PDF 8915k",https://www.pharmapendium.com/browse/fda/Cetirizine Hydrochloride/ddbeb1c7c7307e4b190b04aa63401f86?reference=17,2002.0,OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Ciprofloxacin Hydrochloride,OC(=O)C1=CN(C2CC2)C2=C(C=C(F)C(=C2)N2CCNCC2)C1=O,Hepatic function abnormal,Human,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 021554/S-000 Part 02, page:61 PDF 695k",https://www.pharmapendium.com/browse/fda/Ciprofloxacin Hydrochloride/00c6261a13bbcdf9b9a0147ece522bf9?reference=61,2003.0,OC(=O)C1=CN(C2CC2)C2=C(C=C(F)C(=C2)N2CCNCC2)C1=O
Clomipramine Hydrochloride,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=C(Cl)C=C12,Hepatic function abnormal,Human,-2.3979400086720375,Repeated,Oral,"FDA approval package document: Approval Package 019906/S-001, S-005, S-007, S-013, S-014, S-015, S-016 Part 03, page:20 PDF 6399k",https://www.pharmapendium.com/browse/fda/Clomipramine Hydrochloride/93e55cc14b7332f07420e2fb28ec9907?reference=20,1991.0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=C(Cl)C=C12
Clorazepate Dipotassium,[O-]C(=O)C1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O,Hepatic function abnormal,Human,-1.954242509439325,Repeated,Oral,"FDA approval package document: Approval Package 017105/S-039, S-056, S-008, S-007, S-005, S-004, S-043, S-015, S-016 Part 01, page:45 PDF 5008k",https://www.pharmapendium.com/browse/fda/Clorazepate Dipotassium/83dfb6d62a94a545a1e371a1d4336c4b?reference=45,1972.0,[O-]C(=O)C1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O
Crizotinib,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,Hepatic function abnormal,Human,-2.4771212547196626,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/497137/2012; EMEA/H/C/002489, page:63 PDF 1174k",https://www.pharmapendium.com/browse/ema/Crizotinib/03002030fc9de8da9d419fa9fadd0255?reference=63,2012.0,C[CH](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl
Cromolyn Sodium,OC(COC1=CC=CC2=C1C(=O)C=C(O2)C([O-])=O)COC1=CC=CC2=C1C(=O)C=C(O2)C([O-])=O,Hepatic function abnormal,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 019188 Part 01, page:10 PDF 4066k",https://www.pharmapendium.com/browse/fda/Cromolyn Sodium/5de090eca2f1e844c6419fceb187e82e?reference=10,1989.0,OC(COC1=CC=CC2=C1C(=O)C=C(O2)C([O-])=O)COC1=CC=CC2=C1C(=O)C=C(O2)C([O-])=O
Cyclophosphamide,ClCCN(CCCl)P1(=O)NCCCO1,Hepatic function abnormal,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Label 203856/S-000, page:7 PDF 333k",https://www.pharmapendium.com/browse/fda/Cyclophosphamide/d134b6b0c0f1d60144f6d82dbd25f9e9?reference=7,2013.0,ClCCN(CCCl)P1(=O)NCCCO1
Darolutamide,C[C@@H](CN1C=CC(=N1)C1=CC=C(C#N)C(Cl)=C1)NC(=O)C1=NNC(=C1)C(C)O,Hepatic function abnormal,Human,-2.7781512503836434,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/84124/2020; EMEA/H/C/004790/0000, page:105 PDF 5429k",https://www.pharmapendium.com/browse/ema/Darolutamide/83d84452dfbbcd8a2ca0814b00fb3508?reference=105,2020.0,C[CH](CN1C=CC(=N1)C1=CC=C(C#N)C(Cl)=C1)NC(=O)C1=NNC(=C1)C(C)O
Darunavir Ethanolate,[H][C@]12OCC[C@@]1([H])[C@H](CO2)OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1,Hepatic function abnormal,Human,-3.0791812460476247,Repeated,Oral,"EMA approval document: ANNEX I, page:7 PDF 1145k",https://www.pharmapendium.com/browse/ema/Darunavir Ethanolate/78f0306d47cd485fa60f2cbf44cd810a?reference=7,2020.0,[H][C]12OCC[C]1([H])[CH](CO2)OC(=O)N[CH](CC1=CC=CC=C1)[CH](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1
Deferasirox,OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O,Hepatic function abnormal,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021882/S-000 Part 02, page:85 PDF 5881k",https://www.pharmapendium.com/browse/fda/Deferasirox/0fee9c8dc7b2cc5ecf96f3dfdf7b823c?reference=85,2005.0,OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O
Deferiprone,CN1C=CC(=O)C(O)=C1C,Hepatic function abnormal,Human,-1.8750612633917,Repeated,Oral,"EMA approval document: ANNEX I, page:5 PDF 537k",https://www.pharmapendium.com/browse/ema/Deferiprone/141f1e2a11fa067d0facf8cb661d9cae?reference=5,2021.0,CN1C=CC(=O)C(O)=C1C
Delamanid,C[C@]1(COC2=CC=C(C=C2)N2CCC(CC2)OC2=CC=C(OC(F)(F)F)C=C2)CN2C=C(N=C2O1)N(=O)=O,Hepatic function abnormal,Human,-2.3010299956639813,Repeated,Oral,"EMA approval document: Assessment Report EMA/55567/2014; EMEA/H/C/002552, page:94 PDF 4324k",https://www.pharmapendium.com/browse/ema/Delamanid/e0682a9e8072d93e83504aa96dac2c8e?reference=94,2013.0,C[C]1(COC2=CC=C(C=C2)N2CCC(CC2)OC2=CC=C(OC(F)(F)F)C=C2)CN2C=C(N=C2O1)N(=O)=O
Diclofenac Sodium,[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,Hepatic function abnormal,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Approval Package 019201/S-001, S-002, S-003, S-005, S-007, S-009, S-010, S-013, S-014, S-015, S-019, S-021 Part 04, page:20 PDF 4845k",https://www.pharmapendium.com/browse/fda/Diclofenac Sodium/50a02054fb1c7b2f7fc0318a7d09e44c?reference=20,1988.0,[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
Dirithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O,Hepatic function abnormal,Human,-0.3010299956639812,Repeated,Oral,"FDA approval package document: Approval Package 050678 Part 02, page:20 PDF 5481k",https://www.pharmapendium.com/browse/fda/Dirithromycin/a6c4fabc5a94a7b7f2c880d168e6a978?reference=20,1993.0,CC[CH]1OC(=O)[CH](C)[CH](O[CH]2C[C](C)(OC)[CH](O)[CH](C)O2)[CH](C)[CH](O[CH]2O[CH](C)C[CH]([CH]2O)N(C)C)[C](C)(O)C[CH](C)[CH]2N[CH](COCCOC)O[CH]([CH]2C)[C]1(C)O
Dofetilide,CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1,Hepatic function abnormal,Human,-2.3979400086720375,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020931/S-000 Part 02, page:5 PDF 1807k",https://www.pharmapendium.com/browse/fda/Dofetilide/5c225cab8b2008d3ca8d5e5ab2fd238c?reference=5,1999.0,CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1
Doripenem,[H][C@]12[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,Hepatic function abnormal,Human,-0.9030899869919435,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 022106/S-000 Part 05, page:24 PDF 6399k",https://www.pharmapendium.com/browse/fda/Doripenem/8d34724a2c3a427eeb87f1cbe087fa27?reference=24,2007.0,[H][C]12[CH](C)C(S[CH]3CN[CH](CNS(N)(=O)=O)C3)=C(N1C(=O)[C]2([H])[CH](C)O)C(O)=O
Duloxetine Hydrochloride,CNCC[C@H](OC1=C2C=CC=CC2=CC=C1)C1=CC=CS1,Hepatic function abnormal,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Approval Package 021427/S-039 Part 02, page:1 PDF 1233k",https://www.pharmapendium.com/browse/fda/Duloxetine Hydrochloride/24d4fbfd4ccdc754858ce5fd5769aeb8?reference=1,2011.0,CNCC[CH](OC1=C2C=CC=CC2=CC=C1)C1=CC=CS1
Entacapone,CCN(CC)C(=O)C(\C#N)=C\C1=CC(=C(O)C(O)=C1)N(=O)=O,Hepatic function abnormal,Human,-3.3010299956639813,Repeated,Oral,"EMA approval document: ANNEX I, page:7 PDF 188k",https://www.pharmapendium.com/browse/ema/Entacapone/ec16fd7455529856c5f2928da9d31a56?reference=7,2020.0,CCN(CC)C(=O)C(\C#N)=C\C1=CC(=C(O)C(O)=C1)N(=O)=O
Entrectinib,CN1CCN(CC1)C1=CC=C(C(=O)NC2=NNC3=C2C=C(CC2=CC(F)=CC(F)=C2)C=C3)C(NC2CCOCC2)=C1,Hepatic function abnormal,Human,-2.7781512503836434,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/379739/2020; EMEA/H/C/004936/0000, page:219 PDF 8453k",https://www.pharmapendium.com/browse/ema/Entrectinib/9332dd773f57f5b7f9ce0ceb56ae2bef?reference=219,2020.0,CN1CCN(CC1)C1=CC=C(C(=O)NC2=NNC3=C2C=C(CC2=CC(F)=CC(F)=C2)C=C3)C(NC2CCOCC2)=C1
Eplerenone,[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC,Hepatic function abnormal,Human,-2.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021437/S-002 Part 02, page:17 PDF 1445k",https://www.pharmapendium.com/browse/fda/Eplerenone/fba7cd806ecb9aba1d3c7831115f6b50?reference=17,2003.0,[H][C]12CC[C]3(CCC(=O)O3)[C]1(C)C[CH]1O[C]11[C]2([H])[CH](CC2=CC(=O)CC[C]12C)C(=O)OC
Erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,Hepatic function abnormal,Human,-2.3979400086720375,Repeated,Oral,"FDA approval package document: Label 050536/S-019, page:8 PDF 324k",https://www.pharmapendium.com/browse/fda/Erythromycin/41cde8e40baf313dab5782b3ace42489?reference=8,2006.0,CC[CH]1OC(=O)[CH](C)[CH](O[CH]2C[C](C)(OC)[CH](O)[CH](C)O2)[CH](C)[CH](O[CH]2O[CH](C)C[CH]([CH]2O)N(C)C)[C](C)(O)C[CH](C)C(=O)[CH](C)[CH](O)[C]1(C)O
Erythromycin Ethylsuccinate,[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2OC(=O)CCC(=O)OCC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C,Hepatic function abnormal,Human,-0.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 006205/S-034 Part 03, page:6 PDF 364k",https://www.pharmapendium.com/browse/fda/Erythromycin Ethylsuccinate/bdf04bcb268ada18ca166a2d0fb1d20c?reference=6,2018.0,[H][C]1(C[C](C)(OC)[CH](O)[CH](C)O1)O[CH]1[CH](C)[CH](O[C]2([H])O[CH](C)C[CH]([CH]2OC(=O)CCC(=O)OCC)N(C)C)[C](C)(O)C[CH](C)C(=O)[CH](C)[CH](O)[C](C)(O)[CH](CC)OC(=O)[CH]1C
Esomeprazole Magnesium,COC1=CC=C2[N-]C(=NC2=C1)[S@@](=O)CC1=NC=C(C)C(OC)=C1C,Hepatic function abnormal,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Label 021153/S-025, page:18 PDF 386k",https://www.pharmapendium.com/browse/fda/Esomeprazole Magnesium/4f3362a3b4ca998a2a6866278a897c51?reference=18,2006.0,COC1=CC=C2[N-]C(=NC2=C1)[S](=O)CC1=NC=C(C)C(OC)=C1C
Esomeprazole Sodium,COC1=CC2=C([N-]C(=N2)S(=O)CC2=C(C)C(OC)=C(C)C=N2)C=C1,Hepatic function abnormal,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Label 021689/S-002, page:9 PDF 285k",https://www.pharmapendium.com/browse/fda/Esomeprazole Sodium/e885c81095ed9f549eb5d6bc9f104e28?reference=9,2005.0,COC1=CC2=C([N-]C(=N2)S(=O)CC2=C(C)C(OC)=C(C)C=N2)C=C1
Estradiol,[H][C@]12CC[C@]3(C)[C@@H](O)CC[C@@]3([H])[C@]1([H])CCC1=C2C=CC(O)=C1,Hepatic function abnormal,Human,-2.574031267727719,Repeated,Skin,"FDA approval package document: Approval Package 020538 020323 Part 02, page:66 PDF 3668k",https://www.pharmapendium.com/browse/fda/Estradiol/f54572bda05f5248c6376cb8b0121c3e?reference=66,1996.0,[H][C]12CC[C]3(C)[CH](O)CC[C]3([H])[C]1([H])CCC1=C2C=CC(O)=C1
Etodolac,CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(O)=O,Hepatic function abnormal,Human,-3.0,Repeated,Oral,"FDA approval package document: Approval Package 018922/S-007, S-008, S-013, S-014, S-015 Part 26, page:88 PDF 6654k",https://www.pharmapendium.com/browse/fda/Etodolac/cf790bf1f865041d2f2acca39e9be5e3?reference=88,1991.0,CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(O)=O
Etretinate,CCOC(=O)\C=C(C)\C=C\C=C(C)\C=C\C1=C(C)C(C)=C(OC)C=C1C,Hepatic function abnormal,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Approval Package 019369/S-000, page:43 PDF 4059k",https://www.pharmapendium.com/browse/fda/Etretinate/4c025033beb9f3519d74d667b534ae21?reference=43,1986.0,CCOC(=O)\C=C(C)\C=C\C=C(C)\C=C\C1=C(C)C(C)=C(OC)C=C1C
Ezetimibe,O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1,Hepatic function abnormal,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021445, page:81 PDF 1872k",https://www.pharmapendium.com/browse/fda/Ezetimibe/d98c08aa12fe6ac6fdaf9fa5ecfc9f1b?reference=81,2008.0,O[CH](CC[CH]1[CH](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1
Ezogabine,CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1,Hepatic function abnormal,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022345/S-000 Part 11, page:26 PDF 669k",https://www.pharmapendium.com/browse/fda/Ezogabine/961006b93f4526e78a499b7df750027d?reference=26,2011.0,CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1
Famotidine,N\C(N)=N/C1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1,Hepatic function abnormal,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020325/S-015, page:76 PDF 7378k",https://www.pharmapendium.com/browse/fda/Famotidine/5fa81e4ff6a2de8756c46a0ad36748f1?reference=76,2002.0,N\C(N)=N/C1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
Febuxostat,CC(C)COC1=CC=C(C=C1C#N)C1=NC(C)=C(S1)C(O)=O,Hepatic function abnormal,Human,-2.4771212547196626,Repeated,Oral,"EMA approval document: ANNEX I, page:7 PDF 300k",https://www.pharmapendium.com/browse/ema/Febuxostat/9263bc582cfb24cf942ce6af88777fab?reference=7,2019.0,CC(C)COC1=CC=C(C=C1C#N)C1=NC(C)=C(S1)C(O)=O
Fexofenadine Hydrochloride,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,Hepatic function abnormal,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 201373/S-000 Part 11, page:25 PDF 876k",https://www.pharmapendium.com/browse/fda/Fexofenadine Hydrochloride/d7059e44b20a49f9940c212d18b49443?reference=25,2010.0,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
Fidaxomicin,[H][C@]1(C\C=C(C)\C=C(C)\[C@H](O[C@]2([H])OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]2O)[C@@H](CC)\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(O)C(Cl)=C(O)C(Cl)=C3CC)[C@H](O)[C@@H]2OC)\C(=O)O1)[C@@H](C)O,Hepatic function abnormal,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 201699/S-012 Part 02, page:47 PDF 828k",https://www.pharmapendium.com/browse/fda/Fidaxomicin/fa120d6eeb63606d4e75ce7293ba97b8?reference=47,2020.0,[H][C]1(C\C=C(C)\C=C(C)\[CH](O[C]2([H])OC(C)(C)[CH](OC(=O)C(C)C)[CH](O)[CH]2O)[CH](CC)\C=C(C)\[CH](O)C\C=C\C=C(CO[CH]2O[CH](C)[CH](OC(=O)C3=C(O)C(Cl)=C(O)C(Cl)=C3CC)[CH](O)[CH]2OC)\C(=O)O1)[CH](C)O
Fingolimod Hydrochloride,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1,Hepatic function abnormal,Human,-0.6989700043360189,Repeated,Oral,"EMA approval document: ANNEX I, page:6 PDF 383k",https://www.pharmapendium.com/browse/ema/Fingolimod Hydrochloride/bd73ac06b894a2d8061a1bfd0228a35f?reference=6,2012.0,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1
Flucytosine,NC1=NC(=O)NC=C1F,Hepatic function abnormal,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Label 017001/S-000, page:13 PDF 1236k",https://www.pharmapendium.com/browse/fda/Flucytosine/8b4c46f692806fc09b1eedcba617a43e?reference=13,2009.0,NC1=NC(=O)NC=C1F
Fluoxetine Hydrochloride,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,Hepatic function abnormal,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 018936/S-026 Part 06, page:12 PDF 4533k",https://www.pharmapendium.com/browse/fda/Fluoxetine Hydrochloride/e3b79ff25092347cd3c8634a566a0c6e?reference=12,1987.0,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Fondaparinux Sodium,CO[C@H]1O[C@H](COS([O-])(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS([O-])(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS([O-])(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS([O-])(=O)=O)[C@H](O)[C@H]4O)C([O-])=O)[C@H](OS([O-])(=O)=O)[C@H]3NS([O-])(=O)=O)[C@H](O)[C@H]2OS([O-])(=O)=O)C([O-])=O)[C@H](O)[C@H]1NS([O-])(=O)=O,Hepatic function abnormal,Human,-0.6989700043360189,Repeated,Subcutaneous,"EMA approval document: ANNEX I, page:6 PDF 1162k",https://www.pharmapendium.com/browse/ema/Fondaparinux Sodium/43bbe971badaf392d3fd5107a47411b0?reference=6,2011.0,CO[CH]1O[CH](COS([O-])(=O)=O)[CH](O[CH]2O[CH]([CH](O[CH]3O[CH](COS([O-])(=O)=O)[CH](O[CH]4O[CH]([CH](O[CH]5O[CH](COS([O-])(=O)=O)[CH](O)[CH](O)[CH]5NS([O-])(=O)=O)[CH](O)[CH]4O)C([O-])=O)[CH](OS([O-])(=O)=O)[CH]3NS([O-])(=O)=O)[CH](O)[CH]2OS([O-])(=O)=O)C([O-])=O)[CH](O)[CH]1NS([O-])(=O)=O
Gefitinib,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC(Cl)=C(F)C=C1)=NC=N2,Hepatic function abnormal,Human,-2.3979400086720375,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 206995/S-000 Part 02, page:105 PDF 12992k",https://www.pharmapendium.com/browse/fda/Gefitinib/e765d69482dd54d434698f4ede90d4af?reference=105,2015.0,COC1=CC2=C(C=C1OCCCN1CCOCC1)C(NC1=CC(Cl)=C(F)C=C1)=NC=N2
Glimepiride,CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O,Hepatic function abnormal,Human,-0.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 076802/S-000 Part 01, page:16 PDF 4059k",https://www.pharmapendium.com/browse/fda/Glimepiride/ee930d2eb23075b11a9bad21106e07b4?reference=16,2005.0,CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[CH]2CC[CH](C)CC2)C1=O
Hydroxyurea,NC(=O)NO,Hepatic function abnormal,Human,-1.4771212547196624,Repeated,Oral,"EMA approval document: ANNEX I, page:4 PDF 424k",https://www.pharmapendium.com/browse/ema/Hydroxyurea/b20eeec267520e37b9d7755187f6c23d?reference=4,2020.0,NC(=O)NO
Ibrutinib,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,Hepatic function abnormal,Human,-2.6232492903979003,Repeated,Oral,"FDA approval package document: Approval Package 205552/S-017 Part 04, page:50 PDF 8852k",https://www.pharmapendium.com/browse/fda/Ibrutinib/4b64b73b5f98120f3aa23ee44037f29b?reference=50,2017.0,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[CH]1CCCN(C1)C(=O)C=C
Ibuprofen,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O,Hepatic function abnormal,Human,-3.0791812460476247,Repeated,Oral,"FDA approval package document: Approval Package 018197 Part 02, page:48 PDF 3575k",https://www.pharmapendium.com/browse/fda/Ibuprofen/759409cb3eb9c99756a01fdef5f9305c?reference=48,1980.0,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
Icosapent Ethyl,CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC,Hepatic function abnormal,Human,-3.845098040014257,Repeated,Oral,"FDA approval package document: Pharmacology Review 202057/S-000 Part 05, page:7 PDF 295k",https://www.pharmapendium.com/browse/fda/Icosapent Ethyl/db1c3dffab8ea0038ad137cf629fc8b2?reference=7,2011.0,CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC
Imipramine Hydrochloride,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,Hepatic function abnormal,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Label 087846/S-026, page:2 PDF 283k",https://www.pharmapendium.com/browse/fda/Imipramine Hydrochloride/407c55c284989deef12a3767134016d1?reference=2,2013.0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
Irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1,Hepatic function abnormal,Human,-2.4771212547196626,Repeated,Oral,"EMA approval document: ANNEX I, page:58 PDF 1238k",https://www.pharmapendium.com/browse/ema/Irbesartan/b7fb1f5d5cfcf95dc2a7a3c8fdc4e102?reference=58,2017.0,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1
Itraconazole,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,Hepatic function abnormal,Human,-2.6020599913279625,Repeated,Oral/intravenous,"FDA approval package document: Medical/Clinical Review 020657/S-004, S-005; 020966/S-001, S-003, S-004 Part 03, page:7 PDF 1737k",https://www.pharmapendium.com/browse/fda/Itraconazole/3ac61938995410475e27f19d0e006ddd?reference=7,2000.0,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
Ivosidenib,FC1=CN=CC(=C1)N([C@H](C(=O)NC1CC(F)(F)C1)C1=C(Cl)C=CC=C1)C(=O)[C@@H]1CCC(=O)N1C1=NC=CC(=C1)C#N,Hepatic function abnormal,Human,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 211192/S-000 Part 08, page:45 PDF 4542k",https://www.pharmapendium.com/browse/fda/Ivosidenib/fccdfeb1acee1c5a12b3f529be8acc20?reference=45,2018.0,FC1=CN=CC(=C1)N([CH](C(=O)NC1CC(F)(F)C1)C1=C(Cl)C=CC=C1)C(=O)[CH]1CCC(=O)N1C1=NC=CC(=C1)C#N
Ketoprofen,CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1,Hepatic function abnormal,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Environmental Review 020499/S-000 Part 03, page:15 PDF 1169k",https://www.pharmapendium.com/browse/fda/Ketoprofen/1290668264afac43a077029ae7c5def7?reference=15,1995.0,CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1
Lacosamide,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1,Hepatic function abnormal,Human,-2.7781512503836434,Repeated,Oral/intravenous,"FDA approval package document: Medical/Clinical Review 022253/S-000; 022254/S-000 Part 01, page:88 PDF 7378k",https://www.pharmapendium.com/browse/fda/Lacosamide/bd42e17957ba4fb8e413dec525a3b6de?reference=88,2008.0,COC[CH](NC(C)=O)C(=O)NCC1=CC=CC=C1
Lamotrigine,NC1=NC(N)=C(N=N1)C1=CC=CC(Cl)=C1Cl,Hepatic function abnormal,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Approval Package 022115/S-006 Part 02, page:11 PDF 419k",https://www.pharmapendium.com/browse/fda/Lamotrigine/c840aef9df9edae42d3e870fdc1714c6?reference=11,2011.0,NC1=NC(N)=C(N=N1)C1=CC=CC(Cl)=C1Cl
Lansoprazole,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1,Hepatic function abnormal,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Approval Package 020406 Part 03, page:56 PDF 4102k",https://www.pharmapendium.com/browse/fda/Lansoprazole/09618525313fa9c4e0aeb7c47359985f?reference=56,1995.0,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1
Letermovir,COC1=CC=CC(=C1)N1CCN(CC1)C1=NC2=C(C=CC=C2F)[C@H](CC(O)=O)N1C1=C(OC)C=CC(=C1)C(F)(F)F,Hepatic function abnormal,Human,-2.681241237375587,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/490007/2017; EMEA/H/C/004536/0000, page:101 PDF 3109k",https://www.pharmapendium.com/browse/ema/Letermovir/180cdbdeec542a8be5c987509259fe83?reference=101,2017.0,COC1=CC=CC(=C1)N1CCN(CC1)C1=NC2=C(C=CC=C2F)[CH](CC(O)=O)N1C1=C(OC)C=CC(=C1)C(F)(F)F
Levocetirizine Dihydrochloride,OC(=O)COCCN1CCN(CC1)[C@H](C1=CC=CC=C1)C1=CC=C(Cl)C=C1,Hepatic function abnormal,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022064/S-000 Part 02, page:10 PDF 6317k",https://www.pharmapendium.com/browse/fda/Levocetirizine Dihydrochloride/6e77c5fb26d411d9f53632e63bde15a2?reference=10,2007.0,OC(=O)COCCN1CCN(CC1)[CH](C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Levofloxacin,C[C@H]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O,Hepatic function abnormal,Human,-2.6989700043360187,Repeated,Oral/intravenous,"FDA approval package document: Medical Officer Review 020634/S-000 Part 04, page:97 PDF 6298k",https://www.pharmapendium.com/browse/fda/Levofloxacin/0ced3d5689fa637ae65928a68946a5ac?reference=97,1995.0,C[CH]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
Liraglutide,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O,Hepatic function abnormal,Human,-0.9030899869919435,Repeated,Subcutaneous,"FDA approval package document: Medical/Clinical Review 022341/S-000 Part 04, page:39 PDF 7190k",https://www.pharmapendium.com/browse/fda/Liraglutide/7b7a1616fa508990f2794e56f1ee6a29?reference=39,2009.0,CCCCCCCCCCCCCCCC(=O)N[CH](CCC(=O)NCCCC[CH](NC(=O)[CH](C)NC(=O)[CH](C)NC(=O)[CH](CCC(N)=O)NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](CC(C)C)NC(=O)[CH](CC1=CC=C(O)C=C1)NC(=O)[CH](CO)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC(O)=O)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC1=CC=CC=C1)NC(=O)[CH](NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](C)NC(=O)[CH](N)CC1=CN=CN1)[CH](C)O)[CH](C)O)C(C)C)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CC1=CC=CC=C1)C(=O)N[CH]([CH](C)CC)C(=O)N[CH](C)C(=O)N[CH](CC1=CNC2=C1C=CC=C2)C(=O)N[CH](CC(C)C)C(=O)N[CH](C(C)C)C(=O)N[CH](CCCNC(N)=N)C(=O)NCC(=O)N[CH](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O
Loratadine,CCOC(=O)N1CC\C(CC1)=C1\C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2,Hepatic function abnormal,Human,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 075822/S-000 Part 01, page:24 PDF 5555k",https://www.pharmapendium.com/browse/fda/Loratadine/539bc18269a66ffa31da73a7c296db78?reference=24,2003.0,CCOC(=O)N1CC\C(CC1)=C1\C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2
Lorlatinib,C[C@H]1OC2=CC(=CN=C2N)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=C1C=C(F)C=C2,Hepatic function abnormal,Human,-2.0,Repeated,Oral,"FDA approval package document: Approval Package 210868/S-000 Part 09, page:57 PDF 1228k",https://www.pharmapendium.com/browse/fda/Lorlatinib/bd3ecb44dfc93ea65ade6b9e1d3ea355?reference=57,2018.0,C[CH]1OC2=CC(=CN=C2N)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=C1C=C(F)C=C2
Lusutrombopag,CCCCCCO[C@@H](C)C1=CC=CC(C2=CSC(NC(=O)C3=CC(Cl)=C(\C=C(/C)C(O)=O)C(Cl)=C3)=N2)=C1OC,Hepatic function abnormal,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Approval Package 210923/S-000 Part 05, page:8 PDF 1017k",https://www.pharmapendium.com/browse/fda/Lusutrombopag/94c1442914bb15f9aa4325d07437b0c6?reference=8,2018.0,CCCCCCO[CH](C)C1=CC=CC(C2=CSC(NC(=O)C3=CC(Cl)=C(\C=C(/C)C(O)=O)C(Cl)=C3)=N2)=C1OC
Meloxicam,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=CC=CC=C2S1(=O)=O,Hepatic function abnormal,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 207233/S-000 Part 04, page:47 PDF 9738k",https://www.pharmapendium.com/browse/fda/Meloxicam/0caf0c63e10542b81af2c271442ab2d4?reference=47,2015.0,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=CC=CC=C2S1(=O)=O
Meropenem,[H][C@]12[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,Hepatic function abnormal,Human,-2.0791812460476247,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 202106/S-000 Part 01, page:11 PDF 414k",https://www.pharmapendium.com/browse/fda/Meropenem/a9d24d77bad13f71b4f99ea4f76cccdb?reference=11,2013.0,[H][C]12[CH](C)C(S[CH]3CN[CH](C3)C(=O)N(C)C)=C(N1C(=O)[C]2([H])[CH](C)O)C(O)=O
Mesalamine,NC1=CC(C(O)=O)=C(O)C=C1,Hepatic function abnormal,Human,-3.6989700043360187,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022301/S-000 Part 01, page:57 PDF 6658k",https://www.pharmapendium.com/browse/fda/Mesalamine/bd27fc9deb3575b96265dbabfa9b40fb?reference=57,2008.0,NC1=CC(C(O)=O)=C(O)C=C1
Methylphenidate,COC(=O)C(C1CCCCN1)C1=CC=CC=C1,Hepatic function abnormal,Human,-0.47712125471966244,Repeated,Topical,"FDA approval package document: Approval Package 021514/S-023 Part 01, page:20 PDF 417k",https://www.pharmapendium.com/browse/fda/Methylphenidate/54804c62b2d5b0fd903a23a82071b9f4?reference=20,2015.0,COC(=O)C(C1CCCCN1)C1=CC=CC=C1
Mexiletine Hydrochloride,CC(N)COC1=C(C)C=CC=C1C,Hepatic function abnormal,Human,-0.47712125471966244,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/831802/2018; EMEA/H/C/004584/0000, page:116 PDF 3055k",https://www.pharmapendium.com/browse/ema/Mexiletine Hydrochloride/0339e2432f1279187517a7d5ce5d49a6?reference=116,2018.0,CC(N)COC1=C(C)C=CC=C1C
Micafungin Sodium,[H][C@@]12C[C@@H](O)CN1C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@]1([H])[C@@H](O)[C@@H](C)CN1C(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@H](O)[C@@H](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[C@H](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[C@@H](C)O,Hepatic function abnormal,Human,-0.6989700043360189,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 021506/S-015 Part 09, page:14 PDF 1371k",https://www.pharmapendium.com/browse/fda/Micafungin Sodium/b59ea7e20ea58b45b6dc1acb021a1b7d?reference=14,2012.0,[H][C]12C[CH](O)CN1C(=O)[CH](NC(=O)[CH](C[CH](O)[CH](O)NC(=O)[C]1([H])[CH](O)[CH](C)CN1C(=O)[CH](NC(=O)[CH](NC2=O)[CH](O)[CH](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[CH](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[CH](C)O
Miglustat,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,Hepatic function abnormal,Human,-2.4771212547196626,Repeated,Oral,"EMA approval document: ANNEX I, page:4 PDF 196k",https://www.pharmapendium.com/browse/ema/Miglustat/345890b0476a84066c83d11d00799409?reference=4,2020.0,CCCCN1C[CH](O)[CH](O)[CH](O)[CH]1CO
Milnacipran Hydrochloride,CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C1=CC=CC=C1,Hepatic function abnormal,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022256/S-000 Part 02, page:30 PDF 6827k",https://www.pharmapendium.com/browse/fda/Milnacipran Hydrochloride/4c84f50c0997fbb4cfe3c70b7e24504a?reference=30,2008.0,CCN(CC)C(=O)[C]1(C[CH]1CN)C1=CC=CC=C1
Miltefosine,CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C,Hepatic function abnormal,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 204684/S-000 Part 01, page:30 PDF 685k",https://www.pharmapendium.com/browse/fda/Miltefosine/d578768c04ada62a2f887e64d74423fb?reference=30,2014.0,CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C
Mirabegron,NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1,Hepatic function abnormal,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202611/S-000 Part 21, page:10 PDF 681k",https://www.pharmapendium.com/browse/fda/Mirabegron/67b61f0f8cdefe6bc732447e9a29328f?reference=10,2012.0,NC1=NC(CC(=O)NC2=CC=C(CCNC[CH](O)C3=CC=CC=C3)C=C2)=CS1
Mometasone Furoate,[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Hepatic function abnormal,Human,-2.3010299956639813,Repeated,Inhalation,"FDA approval package document: Medical/Clinical Review 021067/S-000 Part 05, page:9 PDF 4855k",https://www.pharmapendium.com/browse/fda/Mometasone Furoate/8622570c63a1ac3082fb64c33570941c?reference=9,2005.0,[H][C]12C[CH](C)[C](OC(=O)C3=CC=CO3)(C(=O)CCl)[C]1(C)C[CH](O)[C]1(Cl)[C]2([H])CCC2=CC(=O)C=C[C]12C
Moxalactam Disodium,[H][C@]12OCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C(C([O-])=O)C1=CC=C(O)C=C1)OC)C([O-])=O,Hepatic function abnormal,Human,-3.3010299956639813,Repeated,Parenteral,"FDA approval package document: Approval Package 050550 Part 06, page:4 PDF 5788k",https://www.pharmapendium.com/browse/fda/Moxalactam Disodium/b73ec645b0009239490fa19664085432?reference=4,1980.0,[H][C]12OCC(CSC3=NN=NN3C)=C(N1C(=O)[C]2(NC(=O)C(C([O-])=O)C1=CC=C(O)C=C1)OC)C([O-])=O
Mycophenolate Mofetil,COC1=C(C)C2=C(C(=O)OC2)C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1,Hepatic function abnormal,Human,-3.6989700043360187,Repeated,Multiple,"FDA approval package document: Medical/Clinical Review 050722/S-004; 050723/S-003; 050758/S-003; 050759/S-004, page:6 PDF 339k",https://www.pharmapendium.com/browse/fda/Mycophenolate Mofetil/9f618701b847493ca04e5e8e89df44fc?reference=6,2000.0,COC1=C(C)C2=C(C(=O)OC2)C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1
Nevirapine,CC1=CC=NC2=C1NC(=O)C1=C(N=CC=C1)N2C1CC1,Hepatic function abnormal,Human,-0.3010299956639812,Repeated,Oral,"EMA approval document: ANNEX I, page:6 PDF 471k",https://www.pharmapendium.com/browse/ema/Nevirapine/536820943412dcba2ca1be211d94ad91?reference=6,2021.0,CC1=CC=NC2=C1NC(=O)C1=C(N=CC=C1)N2C1CC1
Nicardipine Hydrochloride,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN(C)CC1=CC=CC=C1,Hepatic function abnormal,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 019488 Part 03, page:21 PDF 5470k",https://www.pharmapendium.com/browse/fda/Nicardipine Hydrochloride/9b32ebfd05d2551d00fd7337bd1631f2?reference=21,1988.0,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN(C)CC1=CC=CC=C1
Nilotinib Hydrochloride Monohydrate,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CC=CN=C3)=C(C)C=C2)=C1)C(F)(F)F,Hepatic function abnormal,Human,-2.9030899869919438,Repeated,Oral,"EMA approval document: ANNEX I, page:17 PDF 1383k",https://www.pharmapendium.com/browse/ema/Nilotinib Hydrochloride Monohydrate/f1f0d28ac04823330e8921a3f480f0ab?reference=17,2021.0,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CC=CN=C3)=C(C)C=C2)=C1)C(F)(F)F
Nitisinone,FC(F)(F)C1=CC=C(C(=O)C2C(=O)CCCC2=O)C(=C1)N(=O)=O,Hepatic function abnormal,Human,-0.3010299956639812,Repeated,Oral,"EMA approval document: Scientific Discussion, page:23 PDF 329k",https://www.pharmapendium.com/browse/ema/Nitisinone/0c62cb3e775fc7a38d518fdb19f3281d?reference=23,2005.0,FC(F)(F)C1=CC=C(C(=O)C2C(=O)CCCC2=O)C(=C1)N(=O)=O
Nomifensine,CN1CC(C2=CC=CC=C2)C2=C(C1)C(N)=CC=C2,Hepatic function abnormal,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 018224 Part 01, page:34 PDF 4067k",https://www.pharmapendium.com/browse/fda/Nomifensine/4c17ce40580a0bdf5989d4938bd6678c?reference=34,1984.0,CN1CC(C2=CC=CC=C2)C2=C(C1)C(N)=CC=C2
Nortriptyline Hydrochloride,CNCC\C=C1/C2=CC=CC=C2CCC2=CC=CC=C12,Hepatic function abnormal,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Approval Package 018012/S-024, page:13 PDF 989k",https://www.pharmapendium.com/browse/fda/Nortriptyline Hydrochloride/7a657806f0dd6653e06eb81774032c77?reference=13,2001.0,CNCC\C=C1/C2=CC=CC=C2CCC2=CC=CC=C12
Ofloxacin,CC1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O,Hepatic function abnormal,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 019735/S-052, page:31 PDF 2341k",https://www.pharmapendium.com/browse/fda/Ofloxacin/8ca463a478cff3d02544be358fb903cd?reference=31,2004.0,CC1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
Olanzapine,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2,Hepatic function abnormal,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 020592/S-035, S-039, S-040, S-041, S-049, S-053; 021086/S-021; 021253/S-037 Part 18, page:15 PDF 4099k",https://www.pharmapendium.com/browse/fda/Olanzapine/16545fefc1969725968ab3d64ecfd156?reference=15,2010.0,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
Olopatadine Hydrochloride,CN(C)CC\C=C1\C2=CC=CC=C2COC2=CC=C(CC(O)=O)C=C12,Hepatic function abnormal,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021861/S-000 Part 01, page:68 PDF 1704k",https://www.pharmapendium.com/browse/fda/Olopatadine Hydrochloride/9eb9dbed0818da3a35597e43417acc9f?reference=68,2006.0,CN(C)CC\C=C1\C2=CC=CC=C2COC2=CC=C(CC(O)=O)C=C12
Omeprazole Magnesium,COC1=CC=C2[N-]C(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C,Hepatic function abnormal,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021229/S-000, page:619 PDF 20401k",https://www.pharmapendium.com/browse/fda/Omeprazole Magnesium/42ffe48b5d32d8a231f5c085c007aa78?reference=619,2003.0,COC1=CC=C2[N-]C(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C
Orlistat,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,Hepatic function abnormal,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021887/S-000 Part 01, page:49 PDF 4480k",https://www.pharmapendium.com/browse/fda/Orlistat/3f97e8190e694a8cb2e2e90a1f1afa61?reference=49,2005.0,CCCCCCCCCCC[CH](C[CH]1OC(=O)[CH]1CCCCCC)OC(=O)[CH](CC(C)C)NC=O
Oxcarbazepine,NC(=O)N1C2=CC=CC=C2CC(=O)C2=CC=CC=C12,Hepatic function abnormal,Human,-3.5563025007672873,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021014/S-000 Part 06, page:28 PDF 1647k",https://www.pharmapendium.com/browse/fda/Oxcarbazepine/44b120c1ccabb76ebd73a0eb1292f6c2?reference=28,1999.0,NC(=O)N1C2=CC=CC=C2CC(=O)C2=CC=CC=C12
Paroxetine Hydrochloride,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC=C2OCOC2=C1,Hepatic function abnormal,Human,-1.8750612633917,Repeated,Oral,"FDA approval package document: Approval Package 077873/S-000 Part 03, page:1 PDF 412k",https://www.pharmapendium.com/browse/fda/Paroxetine Hydrochloride/a509e558c60afc1d47a8429b40106097?reference=1,2007.0,FC1=CC=C(C=C1)[CH]1CCNC[CH]1COC1=CC=C2OCOC2=C1
Pazopanib Hydrochloride,CN1N=C2C=C(C=CC2=C1C)N(C)C1=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=NC=C1,Hepatic function abnormal,Human,-2.9030899869919438,Repeated,Oral,"EMA approval document: Assessment Report EMEA/H/C/001141, page:54 PDF 613k",https://www.pharmapendium.com/browse/ema/Pazopanib Hydrochloride/0a109978309581c3085fce67dac7e2fd?reference=54,2010.0,CN1N=C2C=C(C=CC2=C1C)N(C)C1=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=NC=C1
Pemoline,N=C1NC(=O)C(O1)C1=CC=CC=C1,Hepatic function abnormal,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Approval Letter 016832/S-013, page:9 PDF 920k",https://www.pharmapendium.com/browse/fda/Pemoline/528ade209b1e3e530432bb748224ca69?reference=9,1998.0,N=C1NC(=O)C(O1)C1=CC=CC=C1
Penicillamine,CC(C)(S)[C@H](N)C(O)=O,Hepatic function abnormal,Human,-3.0,Repeated,Oral,"FDA approval package document: Approval Package 050491 Part 03, page:22 PDF 4079k",https://www.pharmapendium.com/browse/fda/Penicillamine/4fce7cefd031f12db29058d63670ccc7?reference=22,1978.0,CC(C)(S)[CH](N)C(O)=O
Phenytoin,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1,Hepatic function abnormal,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Approval Package 008762/S-039 Part 02, page:10 PDF 4465k",https://www.pharmapendium.com/browse/fda/Phenytoin/b7b623992fc0883ca467dff66aac3bca?reference=10,2011.0,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1
Phenytoin Sodium,[O-]C1=NC(C(=O)N1)(C1=CC=CC=C1)C1=CC=CC=C1,Hepatic function abnormal,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 040621/S-000 Part 01, page:8 PDF 9629k",https://www.pharmapendium.com/browse/fda/Phenytoin Sodium/54e51c00bc27022bd303d2a10f9b6bd3?reference=8,2006.0,[O-]C1=NC(C(=O)N1)(C1=CC=CC=C1)C1=CC=CC=C1
Pinacidil,CC(C(C)(C)C)\N=C(/NC#N)NC1=CC=NC=C1,Hepatic function abnormal,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Approval Package 019456 Part 10, page:88 PDF 8666k",https://www.pharmapendium.com/browse/fda/Pinacidil/8bfea60c40533a6f4a5037b6cd8ead86?reference=88,1989.0,CC(C(C)(C)C)\N=C(/NC#N)NC1=CC=NC=C1
Pioglitazone Hydrochloride,CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1,Hepatic function abnormal,Human,-1.6532125137753437,Repeated,Oral,"EMA approval document: ANNEX I, page:9 PDF 860k",https://www.pharmapendium.com/browse/ema/Pioglitazone Hydrochloride/d85f24c0d621afa4cec1e6f5543e56a5?reference=9,2014.0,CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
Pirfenidone,CC1=CN(C(=O)C=C1)C1=CC=CC=C1,Hepatic function abnormal,Human,-3.3807537708039,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022535/S-000 Part 01, page:45 PDF 9206k",https://www.pharmapendium.com/browse/fda/Pirfenidone/05a7fa3f06757e7c59dc9121ffea5731?reference=45,2010.0,CC1=CN(C(=O)C=C1)C1=CC=CC=C1
Pitavastatin Calcium,O[C@H](C[C@H](O)\C=C\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC([O-])=O,Hepatic function abnormal,Human,-0.3010299956639812,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022363/S-000 Part 02, page:38 PDF 7655k",https://www.pharmapendium.com/browse/fda/Pitavastatin Calcium/e8281e4f223086197f54edda5d0b953e?reference=38,2008.0,O[CH](C[CH](O)\C=C\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC([O-])=O
Posaconazole,CC[C@@H]([C@H](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@@](C2)(CN2C=NC=N2)C2=C(F)C=C(F)C=C2)C=C1,Hepatic function abnormal,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022027/S-000 Part 01, page:19 PDF 6857k",https://www.pharmapendium.com/browse/fda/Posaconazole/94722ecb0bf0c3bd8506656aa502037c?reference=19,2006.0,CC[CH]([CH](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[CH]2CO[C](C2)(CN2C=NC=N2)C2=C(F)C=C(F)C=C2)C=C1
Pramipexole Dihydrochloride,CCCN[C@H]1CCC2=C(C1)SC(N)=N2,Hepatic function abnormal,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022514/S-000 Part 12, page:11 PDF 329k",https://www.pharmapendium.com/browse/fda/Pramipexole Dihydrochloride/6d25d638b66e6afe6f6b6c20b57e35e6?reference=11,2009.0,CCCN[CH]1CCC2=C(C1)SC(N)=N2
Prasugrel Hydrochloride,CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1,Hepatic function abnormal,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022307/S-000 Part 07, page:2 PDF 876k",https://www.pharmapendium.com/browse/fda/Prasugrel Hydrochloride/0ff7f7bffcacda94e460bee2e04f3c02?reference=2,2007.0,CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1
Propafenone Hydrochloride,CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1,Hepatic function abnormal,Human,-2.9542425094393248,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021416/S-000 Part 03, page:44 PDF 1504k",https://www.pharmapendium.com/browse/fda/Propafenone Hydrochloride/b5a929c4f356880d103269550916a1d9?reference=44,2002.0,CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1
Protriptyline Hydrochloride,CNCCCC1C2=C(C=CC=C2)C=CC2=C1C=CC=C2,Hepatic function abnormal,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Label 073644/S-023; 073645/S-028, page:1 PDF 250k",https://www.pharmapendium.com/browse/fda/Protriptyline Hydrochloride/58d609709725a90acb8fde5cdacf1b9b?reference=1,2014.0,CNCCCC1C2=C(C=CC=C2)C=CC2=C1C=CC=C2
Rabeprazole Sodium,COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3[N-]2)=NC=C1,Hepatic function abnormal,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 020973/S-009 Part 02, page:96 PDF 14721k",https://www.pharmapendium.com/browse/fda/Rabeprazole Sodium/6b3f55d6bf0ad42f82ef4ae04d59ca5e?reference=96,2002.0,COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3[N-]2)=NC=C1
Raloxifene Hydrochloride,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2,Hepatic function abnormal,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022042/S-000 Part 03, page:47 PDF 5461k",https://www.pharmapendium.com/browse/fda/Raloxifene Hydrochloride/58eb58a95868dc2b7fb7f30e50e38887?reference=47,2007.0,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
Ramipril,[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC,Hepatic function abnormal,Human,-0.3010299956639812,Repeated,Oral,"FDA approval package document: Approval Package 019901/S-046, page:5 PDF 315k",https://www.pharmapendium.com/browse/fda/Ramipril/65423e37e6b2eb8bb13b7fd605ec1be6?reference=5,2005.0,[H][C]12CCC[C]1([H])N([CH](C2)C(O)=O)C(=O)[CH](C)N[CH](CCC1=CC=CC=C1)C(=O)OCC
Ranitidine Hydrochloride,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C\N(=O)=O,Hepatic function abnormal,Human,-0.6020599913279624,Repeated,Intravenous,"FDA approval package document: Approval Package 019090/S-017, S-027; 019593/S-011, S-016; 018703/S-040; 019675/S-007 Part 04, page:13 PDF 4063k",https://www.pharmapendium.com/browse/fda/Ranitidine Hydrochloride/90013a3aa49f4ec5a9cf0dd244dab75d?reference=13,1984.0,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C\N(=O)=O
Regorafenib,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1,Hepatic function abnormal,Human,-2.2041199826559246,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/403683/2013; EMEA/H/C/002573/0000, page:77 PDF 1666k",https://www.pharmapendium.com/browse/ema/Regorafenib/38a3e8573c561839e7d1330db89c998e?reference=77,2013.0,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
Relugolix,CONC(=O)NC1=CC=C(C=C1)C1=C(CN(C)C)C2=C(S1)N(CC1=C(F)C=CC=C1F)C(=O)N(C2=O)C1=NN=C(OC)C=C1,Hepatic function abnormal,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Approval Package 214621/S-000 Part 01, page:174 PDF 3111k",https://www.pharmapendium.com/browse/fda/Relugolix/3b681ebde843003de5a19599498faf9a?reference=174,2020.0,CONC(=O)NC1=CC=C(C=C1)C1=C(CN(C)C)C2=C(S1)N(CC1=C(F)C=CC=C1F)C(=O)N(C2=O)C1=NN=C(OC)C=C1
Repaglinide,CCOC1=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=CC=C1C(O)=O,Hepatic function abnormal,Human,-1.2041199826559248,Repeated,Oral,"EMA approval document: ANNEX I, page:7 PDF 583k",https://www.pharmapendium.com/browse/ema/Repaglinide/d71691b4e54937882bf6df4cd204d79c?reference=7,2018.0,CCOC1=CC(CC(=O)N[CH](CC(C)C)C2=CC=CC=C2N2CCCCC2)=CC=C1C(O)=O
Ribavirin,NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,Hepatic function abnormal,Human,-1.1760912590556813,Repeated,Oral,"EMA approval document: ANNEX I, page:15 PDF 511k",https://www.pharmapendium.com/browse/ema/Ribavirin/0f6da39093f1e3353868e51d6fed1035?reference=15,2020.0,NC(=O)C1=NN(C=N1)[CH]1O[CH](CO)[CH](O)[CH]1O
Rifaximin,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C1=C2N=C2C=C(C)C=CN12,Hepatic function abnormal,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021361/S-000 Part 06, page:44 PDF 1496k",https://www.pharmapendium.com/browse/fda/Rifaximin/1294c64e40796c5796329a0b82af91b7?reference=44,2003.0,CO[CH]1\C=C\O[C]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[CH](C)[CH](O)[CH](C)[CH](O)[CH](C)[CH](OC(C)=O)[CH]1C)C1=C2N=C2C=C(C)C=CN12
Riluzole,NC1=NC2=CC=C(OC(F)(F)F)C=C2S1,Hepatic function abnormal,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 020599/S-013 Part 01, page:19 PDF 367k",https://www.pharmapendium.com/browse/fda/Riluzole/fa4c98a71c463b5252ae14a80cc11904?reference=19,2009.0,NC1=NC2=CC=C(OC(F)(F)F)C=C2S1
Risperidone,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,Hepatic function abnormal,Human,-0.7781512503836436,Repeated,Oral,"FDA approval package document: Approval Package 020272/S-036 Part 12, page:17 PDF 2715k",https://www.pharmapendium.com/browse/fda/Risperidone/00d3cf228e8451f91c5b7f27a2f0be5a?reference=17,2006.0,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
Rivaroxaban,ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O,Hepatic function abnormal,Human,-1.3010299956639813,Repeated,Oral,"EMA approval document: ANNEX I, page:36 PDF 1522k",https://www.pharmapendium.com/browse/ema/Rivaroxaban/f7df462dd06876f288288ba9d48e87d0?reference=36,2020.0,ClC1=CC=C(S1)C(=O)NC[CH]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
Saquinavir,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=CC=C3C=CC=CC3=N1)[C@@H](C2)C(=O)NC(C)(C)C,Hepatic function abnormal,Human,-3.0791812460476247,Repeated,Oral,"FDA approval package document: Approval Package 020828/S-015, page:98 PDF 7793k",https://www.pharmapendium.com/browse/fda/Saquinavir/2d541b4caa5ddcb684d0e2d87ade6d61?reference=98,2003.0,[H][C]12CCCC[C]1([H])CN(C[CH](O)[CH](CC1=CC=CC=C1)NC(=O)[CH](CC(N)=O)NC(=O)C1=CC=C3C=CC=CC3=N1)[CH](C2)C(=O)NC(C)(C)C
Selexipag,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C1=CC=CC=C1,Hepatic function abnormal,Human,-3.2041199826559246,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 207947/S-000 Part 05, page:6 PDF 601k",https://www.pharmapendium.com/browse/fda/Selexipag/0a014815d9b037d06801f9864d8abfcb?reference=6,2015.0,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C1=CC=CC=C1
Silodosin,C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=C(OCC(F)(F)F)C=CC=C1,Hepatic function abnormal,Human,-0.9030899869919435,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022206/S-000 Part 02, page:16 PDF 5777k",https://www.pharmapendium.com/browse/fda/Silodosin/4c97fbb5603e0a37c43dc9b7ac0fe9b7?reference=16,2007.0,C[CH](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=C(OCC(F)(F)F)C=CC=C1
Sirolimus,CO[C@@H]1C[C@@H](CC[C@H]1O)C[C@@H](C)[C@@H]1CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1)OC,Hepatic function abnormal,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Administrative documents 021083/S-006 Part 01, page:93 PDF 6695k",https://www.pharmapendium.com/browse/fda/Sirolimus/1267f8f550aab4827b5cd36f113f28dc?reference=93,2003.0,CO[CH]1C[CH](CC[CH]1O)C[CH](C)[CH]1CC(=O)[CH](C)\C=C(C)\[CH](O)[CH](OC)C(=O)[CH](C)C[CH](C)\C=C\C=C\C=C(C)\[CH](C[CH]2CC[CH](C)[C](O)(O2)C(=O)C(=O)N2CCCC[CH]2C(=O)O1)OC
Spirapril Hydrochloride,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(O)=O)SCCS2,Hepatic function abnormal,Human,-1.380211241711606,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020240, page:1 PDF 205k",https://www.pharmapendium.com/browse/fda/Spirapril Hydrochloride/45d43ec541e88cd1f1ab3389f0d8a8d2?reference=1,1993.0,CCOC(=O)[CH](CCC1=CC=CC=C1)N[CH](C)C(=O)N1CC2(C[CH]1C(O)=O)SCCS2
Sulfasalazine,OC(=O)C1=C(O)C=CC(=C1)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1,Hepatic function abnormal,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021243/S-000, page:17 PDF 351k",https://www.pharmapendium.com/browse/fda/Sulfasalazine/d95e9c143487ab782457adcf5f06a0cc?reference=17,2000.0,OC(=O)C1=C(O)C=CC(=C1)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
Sunitinib,CCN(CC)CCNC(=O)C1=C(C)NC(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C,Hepatic function abnormal,Human,-1.8750612633917,Repeated,Oral,"EMA approval document: ANNEX I, page:11 PDF 705k",https://www.pharmapendium.com/browse/ema/Sunitinib/95d35eea3df7c71029f241d18fa5927a?reference=11,2021.0,CCN(CC)CCNC(=O)C1=C(C)NC(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C
Tacrolimus,[H][C@]12O[C@](O)([C@H](C)C[C@@H]1OC)C(=O)C(=O)N1CCCC[C@H]1C(=O)O[C@@H]([C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)\C=C(C)\C[C@H](C)C[C@@H]2OC)C(\C)=C\[C@H]1CC[C@@H](O)[C@H](C1)OC,Hepatic function abnormal,Human,-0.47712125471966244,Repeated,Oral,"EMA approval document: ANNEX I, page:7 PDF 363k",https://www.pharmapendium.com/browse/ema/Tacrolimus/ddd3b1dc3f5b88ac9eef8ad12572c596?reference=7,2020.0,[H][C]12O[C](O)([CH](C)C[CH]1OC)C(=O)C(=O)N1CCCC[CH]1C(=O)O[CH]([CH](C)[CH](O)CC(=O)[CH](CC=C)\C=C(C)\C[CH](C)C[CH]2OC)C(\C)=C\[CH]1CC[CH](O)[CH](C1)OC
Tadalafil,[H][C@]12CC3=C(NC4=C3C=CC=C4)[C@H](N1C(=O)CN(C)C2=O)C1=CC=C2OCOC2=C1,Hepatic function abnormal,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Approval Package 021368/S-020 Part 25, page:54 PDF 5445k",https://www.pharmapendium.com/browse/fda/Tadalafil/673cccc359eabaa469bf6c8a5274b4e6?reference=54,2011.0,[H][C]12CC3=C(NC4=C3C=CC=C4)[CH](N1C(=O)CN(C)C2=O)C1=CC=C2OCOC2=C1
Telithromycin,[H][C@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CN=CC=C1,Hepatic function abnormal,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Approval Package 021144/S-012, page:53 PDF 657k",https://www.pharmapendium.com/browse/fda/Telithromycin/3525544120b4529175fd8596ec3552c0?reference=53,2007.0,[H][C]12[CH](C)C(=O)[CH](C)C[C](C)(OC)[CH](O[CH]3O[CH](C)C[CH]([CH]3O)N(C)C)[CH](C)C(=O)[CH](C)C(=O)O[CH](CC)[C]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CN=CC=C1
Telmisartan,CCCC1=NC2=C(C)C=C(C=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O)C1=NC2=CC=CC=C2N1C,Hepatic function abnormal,Human,-1.9030899869919435,Repeated,Oral,"EMA approval document: Procedural Steps EMA/696616/2020, page:12 PDF 321k",https://www.pharmapendium.com/browse/ema/Telmisartan/d9f633988a5eff91cd03fa95477c380e?reference=12,2020.0,CCCC1=NC2=C(C)C=C(C=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O)C1=NC2=CC=CC=C2N1C
Teriflunomide,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F,Hepatic function abnormal,Human,-1.146128035678238,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202992/S-000 Part 12, page:58 PDF 11938k",https://www.pharmapendium.com/browse/fda/Teriflunomide/9711c01cf59f491dbbc62266f7c8962f?reference=58,2012.0,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F
Tigecycline,[H][C@@]12CC3=C(C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)C(O)=C(NC(=O)CNC(C)(C)C)C=C3N(C)C,Hepatic function abnormal,Human,-1.0791812460476249,Repeated,Intravenous,"FDA approval package document: Approval Package 021821/S-026, S-031 Part 01, page:15 PDF 2001k",https://www.pharmapendium.com/browse/fda/Tigecycline/f1d463cdaae9f608ea1b859013e830ef?reference=15,2013.0,[H][C]12CC3=C(C(=O)C1=C(O)[C]1(O)C(=O)C(C(N)=O)=C(O)[CH](N(C)C)[C]1([H])C2)C(O)=C(NC(=O)CNC(C)(C)C)C=C3N(C)C
Tizanidine Hydrochloride,ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1,Hepatic function abnormal,Human,-1.5563025007672873,Repeated,Oral,"FDA approval package document: Medical Officer Review 020397, page:11 PDF 728k",https://www.pharmapendium.com/browse/fda/Tizanidine Hydrochloride/fadd8cf1a4115fd6ce090d88629487af?reference=11,1994.0,ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1
Tolvaptan,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2,Hepatic function abnormal,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 204441/S-000 Part 04, page:33 PDF 6589k",https://www.pharmapendium.com/browse/fda/Tolvaptan/1855f2995f8ec9e519b7402d7140e3ad?reference=33,2013.0,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2
Topiramate,[H][C@@]12OC(C)(C)O[C@]1(COS(N)(=O)=O)OC[C@H]1OC(C)(C)O[C@@H]21,Hepatic function abnormal,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020505 Part 02, page:40 PDF 2644k",https://www.pharmapendium.com/browse/fda/Topiramate/0e67447c530fa1dbad411867aea35c0c?reference=40,1995.0,[H][C]12OC(C)(C)O[C]1(COS(N)(=O)=O)OC[CH]1OC(C)(C)O[CH]21
Trandolapril,[H][C@]12CCCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC,Hepatic function abnormal,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 020528/S-001 Part 02, page:14 PDF 1012k",https://www.pharmapendium.com/browse/fda/Trandolapril/281895f55f444bcb4024286951c134cb?reference=14,1996.0,[H][C]12CCCC[C]1([H])N([CH](C2)C(O)=O)C(=O)[CH](C)N[CH](CCC1=CC=CC=C1)C(=O)OCC
Troleandomycin,CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1OC(C)=O)O[C@H]1[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(C)=O)N(C)C)[C@@H](C)C[C@@]2(CO2)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]1C,Hepatic function abnormal,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 050331, page:8 PDF 957k",https://www.pharmapendium.com/browse/fda/Troleandomycin/dce5622b265f7916994bc3b9c240a58f?reference=8,1959.0,CO[CH]1C[CH](O[CH](C)[CH]1OC(C)=O)O[CH]1[CH](C)[CH](O[CH]2O[CH](C)C[CH]([CH]2OC(C)=O)N(C)C)[CH](C)C[C]2(CO2)C(=O)[CH](C)[CH](OC(C)=O)[CH](C)[CH](C)OC(=O)[CH]1C
Ulipristal Acetate,[H][C@@]12CCC3=CC(=O)CCC3=C1[C@H](C[C@@]1(C)[C@@]2([H])CC[C@]1(OC(C)=O)C(C)=O)C1=CC=C(C=C1)N(C)C,Hepatic function abnormal,Human,-1.0,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/84021/2015; EMEA/H/C/002041/II/0028, page:46 PDF 4975k",https://www.pharmapendium.com/browse/ema/Ulipristal Acetate/88e54d22b1add642a5687c34a8150a02?reference=46,2015.0,[H][C]12CCC3=CC(=O)CCC3=C1[CH](C[C]1(C)[C]2([H])CC[C]1(OC(C)=O)C(C)=O)C1=CC=C(C=C1)N(C)C
Valganciclovir Hydrochloride,CC(C)[C@H](N)C(=O)OCC(CO)OCN1C=NC2=C1N=C(N)NC2=O,Hepatic function abnormal,Human,-2.9542425094393248,Repeated,Oral,"FDA approval package document: Approval Package 021304/S-001, page:80 PDF 9958k",https://www.pharmapendium.com/browse/fda/Valganciclovir Hydrochloride/e1a774ff88ed603671c561aabe592add?reference=80,2003.0,CC(C)[CH](N)C(=O)OCC(CO)OCN1C=NC2=C1N=C(N)NC2=O
Vemurafenib,CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1,Hepatic function abnormal,Human,-2.9822712330395684,Repeated,Oral,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 202429/S-000 Part 03, page:1 PDF 401k",https://www.pharmapendium.com/browse/fda/Vemurafenib/a71b0db58dca16a4f0e78174d14ccf9f?reference=1,2011.0,CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1
Vibegron,[H][C@@]1(CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)[C@H](O)C1=CC=CC=C1,Hepatic function abnormal,Human,-1.8750612633917,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 213006/S-000 Part 02, page:115 PDF 17037k",https://www.pharmapendium.com/browse/fda/Vibegron/691bda3e930a665761d8dd10d8b3c962?reference=115,2020.0,[H][C]1(CC[CH](CC2=CC=C(NC(=O)[CH]3CCC4=NC=CC(=O)N34)C=C2)N1)[CH](O)C1=CC=CC=C1
Vidarabine,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,Hepatic function abnormal,Human,-1.0,Repeated,Intravenous,"FDA approval package document: Approval Package 050523, page:57 PDF 6146k",https://www.pharmapendium.com/browse/fda/Vidarabine/2f5df6b2c70ad513d76a070d1f5b0b66?reference=57,1983.0,NC1=NC=NC2=C1N=CN2[CH]1O[CH](CO)[CH](O)[CH]1O
Vigabatrin,NC(CCC(O)=O)C=C,Hepatic function abnormal,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020427/S-000 Part 04, page:18 PDF 6783k",https://www.pharmapendium.com/browse/fda/Vigabatrin/f04e0c3002c7e886d0386351669d22f5?reference=18,2009.0,NC(CCC(O)=O)C=C
Vildagliptin,[H][C@]12C[C@]3([H])C[C@](O)(C1)C[C@](C2)(C3)NCC(=O)N1CCC[C@@H]1C#N,Hepatic function abnormal,Human,-2.0,Repeated,Oral,"EMA approval document: ANNEX I, page:4 PDF 534k",https://www.pharmapendium.com/browse/ema/Vildagliptin/175999fa7b38ec4130f628d7f44e8908?reference=4,2020.0,[H][C]12C[C]3([H])C[C](O)(C1)C[C](C2)(C3)NCC(=O)N1CCC[CH]1C#N
Voriconazole,C[C@@H](C1=C(F)C=NC=N1)[C@](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F,Hepatic function abnormal,Human,-0.6020599913279624,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 208562/S-000, page:11 PDF 3069k",https://www.pharmapendium.com/browse/fda/Voriconazole/429feb21ab25ea7c397fc2dcb560c640?reference=11,2016.0,C[CH](C1=C(F)C=NC=N1)[C](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F
Zafirlukast,COC1=CC(=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2)C(=O)NS(=O)(=O)C1=CC=CC=C1C,Hepatic function abnormal,Human,-1.0,Repeated,Oral,"FDA approval package document: Label 020547/S-029, page:20 PDF 1194k",https://www.pharmapendium.com/browse/fda/Zafirlukast/244ecd1e992ff73be2fed108af9f0eb5?reference=20,2009.0,COC1=CC(=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2)C(=O)NS(=O)(=O)C1=CC=CC=C1C
Zalcitabine,NC1=NC(=O)N(C=C1)[C@H]1CC[C@@H](CO)O1,Hepatic function abnormal,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Approval Package 020199 Part 01, page:21 PDF 3966k",https://www.pharmapendium.com/browse/fda/Zalcitabine/7516791f2c2ebfd4e1d211931a39b97b?reference=21,1992.0,NC1=NC(=O)N(C=C1)[CH]1CC[CH](CO)O1
Zanamivir,[H][C@]1(OC(=C[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O)[C@H](O)[C@H](O)CO,Hepatic function abnormal,Human,-2.7781512503836434,Repeated,Intravenous,"EMA approval document: Public Assessment Report EMA/CHMP/851480/2018; EMEA/H/C/004102/0000, page:111 PDF 2375k",https://www.pharmapendium.com/browse/ema/Zanamivir/0160f7132f67bf85b6bfb2d976c2fd6f?reference=111,2019.0,[H][C]1(OC(=C[CH](NC(N)=N)[CH]1NC(C)=O)C(O)=O)[CH](O)[CH](O)CO
Zileuton,CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1,Hepatic function abnormal,Human,-3.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022052/S-000 Part 01, page:42 PDF 6670k",https://www.pharmapendium.com/browse/fda/Zileuton/4a209ce23ae39ed1019cac5be7b004c0?reference=42,2007.0,CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
Zomepirac,CN1C(CC(O)=O)=CC(C)=C1C(=O)C1=CC=C(Cl)C=C1,Hepatic function abnormal,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 018236/S-008, S-009, S-015, S-017, S-018, S-024 Part 02, page:6 PDF 5050k",https://www.pharmapendium.com/browse/fda/Zomepirac/0b348a66d2f74804d192bcee4ba5cf23?reference=6,1983.0,CN1C(CC(O)=O)=CC(C)=C1C(=O)C1=CC=C(Cl)C=C1
Zonisamide,NS(=O)(=O)CC1=NOC2=CC=CC=C12,Hepatic function abnormal,Human,-0.9030899869919435,Repeated,Oral,"EMA approval document: Assessment Report EMA/470045/2013; EMEA/H/C/000577/II/0065, page:48 PDF 1046k",https://www.pharmapendium.com/browse/ema/Zonisamide/a7acf6027fd446290de64f99269548e6?reference=48,2013.0,NS(=O)(=O)CC1=NOC2=CC=CC=C12
